key: cord-0897584-2im90mts
authors: Deutsch-Feldman, Molly; Pratt, Robert H.; Price, Sandy F.; Tsang, Clarisse A.; Self, Julie L.
title: Tuberculosis — United States, 2020
date: 2021-03-26
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7012a1
sha: 4ec1a973b204639de66b7581650df2a796bb2d84
doc_id: 897584
cord_uid: 2im90mts

Tuberculosis (TB) disease incidence has decreased steadily since 1993 (1), a result of decades of work by local TB programs to detect, treat, and prevent TB disease and transmission. During 2020, a total of 7,163 TB cases were provisionally reported to CDC's National Tuberculosis Surveillance System (NTSS) by the 50 U.S. states and the District of Columbia (DC), a relative reduction of 20%, compared with the number of cases reported during 2019.* TB incidence per 100,000 persons was 2.2 during 2020, compared with 2.7 during 2019. Since 2010, TB incidence has decreased by an average of 2%-3% annually (1). Pandemic mitigation efforts and reduced travel might have contributed to the reported decrease. The magnitude and breadth of the decrease suggest potentially missed or delayed TB diagnoses. Health care providers should consider TB disease when evaluating patients with signs and symptoms consistent with TB (e.g., cough of >2 weeks in duration, unintentional weight loss, and hemoptysis), especially when diagnostic tests are negative for SARS-CoV-2, the virus that causes COVID-19. In addition, members of the public should be encouraged to follow up with their health care providers for any respiratory illness that persists or returns after initial treatment. The steep, unexpected decline in TB cases raises concerns of missed cases, and further work is in progress to better understand factors associated with the decline.

Tuberculosis (TB) disease incidence has decreased steadily since 1993 (1), a result of decades of work by local TB programs to detect, treat, and prevent TB disease and transmission. During 2020, a total of 7,163 TB cases were provisionally reported to CDC's National Tuberculosis Surveillance System (NTSS) by the 50 U.S. states and the District of Columbia (DC), a relative reduction of 20%, compared with the number of cases reported during 2019.* TB incidence per 100,000 persons was 2.2 during 2020, compared with 2.7 during 2019. Since 2010, TB incidence has decreased by an average of 2%-3% annually (1) . Pandemic mitigation efforts and reduced travel might have contributed to the reported decrease. The magnitude and breadth of the decrease suggest potentially missed or delayed TB diagnoses. Health care providers should consider TB disease when evaluating patients with signs and symptoms consistent with TB (e.g., cough of >2 weeks in duration, unintentional weight loss, and hemoptysis), especially when diagnostic tests are negative for SARS-CoV-2, the virus that causes COVID-19. In addition, members of the public should be encouraged to follow up with their health care providers for any respiratory illness that persists or returns after initial treatment. The steep, unexpected decline in TB cases raises concerns of missed cases, and further work is in progress to better understand factors associated with the decline.

Health departments in the 50 U.S. states and DC report cases of TB to CDC based on the Council for State and Territorial Epidemiologists' surveillance definition, which includes both laboratory and clinically verified cases. † For each case, health departments electronically submit a report of a verified case of TB to CDC. Although certain jurisdictions reported disruptions to routine TB prevention activities early in the pandemic (2), all reporting areas provided provisional reporting data to incidence per 100,000 persons. Case reports were grouped on the basis of self-reported race and ethnicity according to federal guidelines. ¶ Persons self-reporting Hispanic ethnicity are categorized as Hispanic regardless of self-reported race, persons not reporting Hispanic ethnicity are categorized by self-reported race, and non-Hispanic persons who self-reported more than one race are categorized as "multiple races." Midyear population estimates from the Current Population Survey** were used to calculate incidence by national origin and race/ethnicity.

A total of 7,163 TB cases were reported during 2020 (2.2 cases per 100,000 persons), 20% fewer than during 2019 (2.7 cases per 100,000 persons). Thirty-nine states and DC reported a decrease in cases, eight states reported an increase, and three reported no change. California reported the highest number of cases (1, 703) , and Alaska reported the highest incidence (7.9 cases per 100,000 persons) ( Table 1 ). The East North Central region experienced the largest decrease in TB incidence (−25%).

During 2020, 71% of TB cases occurred among non-U.S.-born † † persons, the same proportion as in 2019. Incidence decreased among both U.S.-born (0.9 to 0.7 cases per 100,000 persons) and non-U.S.-born persons (14.2 to 11.5 cases per 100,000 persons) (Figure) . 

TB cases and incidence have decreased gradually since the peak of resurgence in 1992 (1), highlighting the impact of nationwide TB control efforts. Although steep decreases have been reported previously, most notably after the 2008 economic recession (3), the annual decrease reported during 2020 is far larger than any reported during the last decade (1). Similar trends in TB have been reported globally (4) and for other diseases domestically (5, 6) . Multiple factors have likely led to both a true decrease in TB incidence and underascertainment of cases.

The reduction in the number of persons with TB disease reported ≤1 year after arrival in the United States indicates that changes in immigration and travel patterns during 2020 might have contributed to a decrease in TB incidence. However, given the large proportion of cases that occur each year among persons who have been in the United States >1 year, particularly those who have been in the United States >10 years (7) , and the broad decreases reported among both non-U.S.-born and U.S.-born populations, immigration and travel changes cannot fully explain the decrease in the number of reported TB cases during 2020. Another possible cause of this decrease is that mitigation strategies implemented for slowing the spread of COVID-19 (e.g., mask-wearing and social distancing) might have also reduced TB transmission.

The unexpectedly steep and widespread reduction in the number of reported TB cases causes concern regarding underdiagnosis. CDC has received anecdotal reports of persons who repeatedly sought medical attention for persistent TB signs and symptoms, received a negative test result for SARS-CoV-2 multiple times, and received a TB diagnosis much later (in certain cases on autopsy), demonstrating that other TB cases might have been missed during 2020. TB should be considered in the differential diagnosis of patients with prolonged (>2 weeks) cough or TB symptoms such as unintentional weight loss, particularly in the context of negative tests for SARS-CoV-2 and epidemiologic risk factors for TB (e.g., birth or former residence in a country with high TB incidence, a history of living in a congregate setting such as a homeless shelter or a correctional facility, or immune suppression). In such cases, health care providers should consider ordering rapid TB diagnostic tests (e.g., sputum microscopy or nucleic acid amplification tests) to quickly identify patients with TB disease. Clinical consultation for potential TB cases is also available through TB programs or the CDC-sponsored TB Centers of Excellence.*** Limited access to and reluctance to seek medical care during the COVID-19 pandemic have been reported (8) and might also contribute to underdiagnosis. Persons with persistent respiratory symptoms should be encouraged to seek medical attention and return to a health care provider if symptoms persist or return despite initial treatment (8, 9) . Timely TB diagnoses save lives and prevent further community transmission.

The findings in this report are subject to at least two limitations. First, this analysis is limited to provisional TB surveillance data reported for 2020. In previous years, final case counts have not differed substantially from provisional data. However, although anecdotal information from reporting areas *** https://www.cdc.gov/tb/education/professionaltools.htm demonstrates that underreporting is not a major contributor to the reported decrease in TB incidence during 2020, underreporting from providers and underdiagnosis are possible. Second, denominators used to calculate incidence are based on estimated population numbers and might change slightly if population estimates are adjusted.

Further work is in progress to examine the causes of the steep decrease in reported TB cases. The extent of underdiagnosis will be explored by using external data sources of mortality, TB hospitalization, and anti-TB drug dispensation. Further analysis of laboratory data and conversations with clinical infection preventionists will help determine the extent of underreporting. In addition, changes in recent transmission will be examined by using isolate genotyping data. Identifying reversible causes of underdiagnosis or actual causes of an actual reduction in TB cases during 2020 will help identify effective public health responses. Supporting public health infrastructure for performing fundamental principles of TB control (e.g., case detection, contact tracing, and targeted testing and treatment for latent TB infection) is important. CDC remains committed to working with its public health partners to eliminate TB in the United States.

US Department of Health and Human Services, CDC

Notes from the field: effects of the COVID-19 response on tuberculosis prevention and control efforts-United States

What is added by this report? TB incidence during 2020 (2.2 cases per 100,000 persons) was 20% lower than that during 2019 (2.7 cases). The relative decrease in incidence was similar among U.S.-born and non-U.S.-born persons. What are the implications for public health practice? The steep decrease in TB incidence during the COVID-19 pandemic might be the result of reduced transmission and undetected cases. Health care providers should consider TB disease in patients with signs and symptoms consistent with TB, and the public should be encouraged to seek medical care when needed

Unexpected decline in tuberculosis cases coincident with economic recession-United States

Effect of COVID-19 on tuberculosis notification

Decreases in young children who received blood lead level testing during COVID-19-34 jurisdictions

Impact of COVID-19 on cervical cancer screening rates among women aged 21-65 years in a large integrated health care system-Southern California

US tuberculosis rates among persons born outside the United States compared with rates in their countries of birth

Delay or avoidance of medical care because of COVID-19-related concerns-United States

Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions-United States